480 Preliminary evaluation of a novel coronavirus vaccine (CORVax) using electroporation of plasmid DNA encoding a stabilized prefusion SARS-CoV-2 spike protein alone or with transfection of plasmid IL-12Shawn M. Jensen, Bernard A. Fox, Christopher G. Twitty et al.|Regular and Young Investigator Award Abstracts|2020Cited by 5
Abstract CT112: An off-the-shelf multivalent vaccine containing cancer’s dark matter, DPV-001, combined with PD-1 +/- GITR in head & neck cancer: safety, efficacy, and immunodynamics from the phase 1 GITRVax trialRom S. Leidner, Bernard A. Fox, Tarsem Moudgil et al.|Cancer Research|2024Cited by 3
1481 Off-the-shelf dark matter immunotherapy in head & neck cancer: mechanistic insights and clinical efficacyRom S. Leidner, Bernard A. Fox, Christopher Paustian et al.|Unknown|2024Cited by 1
Abstract CT123: Trial in progress: First-in-human immunotherapy-trio for advanced head and neck squamous cell carcinomaMarcus Couey, Rom S. Leidner, Matthew Taylor et al.|Cancer Research|2023Cited by 0
680 Multi-parametric assessment of the immune response to a trio immunotherapy in patients with recurrent or metastatic head and neck squamous cell carcinomaChristopher Paustian, Rom S. Leidner, Tarsem Moudgil et al.|Regular and Young Investigator Award Abstracts|2023Cited by 0